Hormonal
Subcutaneous semaglutide at a maintenance dose of 2.4 mg once weekly produces clinically significant weight loss (mean reduction ~14-16%) in non-diabetic adults with obesity or overweight, significantly outperforming placebo.
For non-diabetic adults with obesity or overweight, weekly subcutaneous semaglutide (2.4 mg) is a highly effective treatment for weight loss, achieving an average 15% body weight reduction. This is significantly better than placebo or other existing medications. Treatment involves a gradual dose increase over 16 weeks to minimize side effects, combined with a calorie-restricted diet and exercise. Patients should be aware that stopping the medication often leads to weight regain, suggesting it may be a long-term therapy.
The consolidated data from the literature in this systematic review endorses the use of semaglutide as a highly efficient weight-reducing agent... In contrast to other classes of weight loss agents, which have not exceeded 10% of initial body weight loss at chronic tolerable dose administration, GLP-1 agent semaglutide has shown 14.9% body weight reduction in clinical trials [6].
Why this rating
Based on a systematic review of 9 RCTs and 1 retrospective cohort study, with high-quality appraisal (Cochrane RoB 2.0 and NOS).
Source
Efficacy of Different Doses and Forms of the GLP-1 Receptor Agonist Semaglutide in Weight Reduction Among Non-diabetic Obese or Overweight Populations
Nazeefa Fatima et al. · Cureus · 2024
DOI 10.7759/cureus.68786
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →